TG Therapeutics (TGTX) has become a focal point after releasing early Phase 1 data on azercabtagene zapreleucel in progressive multiple sclerosis, giving investors fresh clinical information to weigh against the current valuation.
The fresh azer-cel data has landed while TG Therapeutics' share price has been on a strong run, with a 1-day share price return of 3.01% and a year to date share price return of 92.76% off a last close of US$56.44.
Short term, the picture is more mixed, with the 30 day share price return down 1.72% even as the 90 day share price return is 5.53%. This hints that momentum cooled recently after a powerful earlier move.
Looking further out, total shareholder return of 63.36% over one year and roughly 7x over three years shows how tightly the TG Therapeutics story has been linked to changing expectations around its MS portfolio and perceived execution risk.
Scan other MS-focused and healthcare AI players riding similar clinical catalysts with a curated set of 34 healthcare AI stocks that echo the TG Therapeutics story.
TG Therapeutics now appears to be a serious MS platform rather than a single-drug story. After a move this strong, the real work is determining whether that quality is already fully reflected in the share price.
Most Popular Narrative: 19% Undervalued
TG Therapeutics is trading at $56.44 against a widely followed fair value anchor of $69.71, so the key question is whether the current MS and autoimmune story really supports that gap.
The planned launch of subcutaneous BRIUMVI remains a key upcoming catalyst, as it targets the 35 to 40% of the anti CD20 multiple sclerosis market that is currently in self administered products where TG Therapeutics does not yet participate. This could materially affect future revenue and earnings.
The fully enrolled Phase 3 program for subcutaneous BRIUMVI, supported by Phase 1 data indicating around 60% bioavailability and acceptable injection tolerability and guided toward a potential 2028 launch, could allow TG Therapeutics to participate in both infusion and self administered anti CD20 segments and affect top line growth and operating leverage.
See why 73 investors see TG Therapeutics as 19% undervalued .
Result: Fair Value of $69.71 (UNDERVALUED)
Still, the bullish TG Therapeutics narrative can break if manufacturing spending fails to deliver viable subcutaneous products, or if governance investigations disrupt execution and capital allocation.
Find out about the key risks to this TG Therapeutics narrative .
Next Steps
Mixed opinions like these only matter if you stress test them yourself, so take a close look at both sides of the TG Therapeutics story and weigh the 4 key rewards and 1 important warning sign .
Looking for more investment ideas beyond TG Therapeutics?
If the TG Therapeutics story has sharpened your focus, do not stop here. Broaden your watchlist now or you risk missing the next opportunity.
-
Target potential value plays by scanning a curated set of 29 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them yet.
-
Strengthen your defensive side by reviewing a list of solid balance sheet and fundamentals (24 results) that can help anchor a portfolio when conditions get choppy.
-
Get ahead of the crowd by tracking a 21 high quality undiscovered gems that may not be widely followed but already show compelling financial traits.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TGTX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
